Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Shah Prem S

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/1/2022

3. Issuer Name and Ticker or Trading Symbol

CVS HEALTH Corp [CVS]

(Last) (First) (Middle)

ONE CVS DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
EVP and Co-President of Retail /

(Street)

WOONSOCKET, RI 02895

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11980.24	D
Common Stock (restricted) ⁽¹⁾	575	D
Common Stock (restricted) ⁽²⁾	2884	D
Common Stock (restricted) ⁽³⁾	15427	D
Common Stock (restricted) ⁽⁴⁾	1808	D
Common Stock (restricted) ⁽⁵⁾	1925	D
Common Stock (restricted) ⁽⁶⁾	6393	D
Common Stock (restricted) ⁽⁷⁾	4372.62	D
Common Stock (restricted) ⁽⁸⁾	2798	D
Stock Unit (deferred) ⁽⁹⁾	5625.28	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option ⁽¹⁰⁾	4/1/2017	4/1/2023	Common Stock	5870	$104.82	D
Stock Option ⁽¹¹⁾	4/1/2016	4/1/2022	Common Stock	5346	$102.26	D
Stock Option ⁽¹²⁾	4/1/2019	4/1/2025	Common Stock	1691	$62.2011	D
Stock Option ⁽¹³⁾	4/1/2020	4/1/2029	Common Stock	12626	$54.19	D
Stock Option ⁽¹⁴⁾	4/1/2021	4/1/2030	Common Stock	34315	$58.34	D
Stock Option ⁽¹⁵⁾	4/1/2022	4/1/2031	Common Stock	32826	$74.30	D
Stock Option ⁽¹⁶⁾	8/31/2021	8/31/2028	Common Stock	26580	$75.24	D

Explanation of Responses:
(1)	Consists of remaining Restricted Stock Units (RSUs) awarded pursuant to Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 Incentive Compensation Plan (ICP). Restrictions lapse on 02/28/2022.
(2)	Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in two equal installments commencing on 04/01/2022.
(3)	Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in three equal installments commencing on 04/01/2022.
(4)	Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions lapse on 04/01/2022.
(5)	Consists of remaining RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 ICP. Restrictions lapse in two equal installments commencing on 02/28/2022.
(6)	Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in four equal installments commencing on 04/01/2022.
(7)	Consists of Matching RSUs awarded pursuant to Issuer's Partnership Equity Program, a sub-plan under its ICP, and dividend equivalents on the Matching RSUs. Restrictions lapse on the RSUs on 08/31/2023.
(8)	Consists of RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan under its 2017 ICP. Restrictions lapse in three equal installments commencing on 02/26/2022.
(9)	Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
(10)	Option becomes exercisable in four equal installments commencing 04/01/2017.
(11)	Option becomes exercisable in four equal installments commencing 04/01/2016.
(12)	Option becomes exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
(13)	Option becomes exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised.
(14)	Option becomes exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
(15)	Option becomes exercisable in three equal installments commencing 04/01/2022.
(16)	Option vests in three equal installments, on 8/31/2021, 8/31/2022 and 8/31/2023.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Shah Prem S ONE CVS DRIVE WOONSOCKET, RI 02895			EVP and Co-President of Retail